BACKGROUND AND AIM: Patients with advanced liver disease due to thrombocytopenia and chronic infection with hepatitis C virus (HCV) are difficult to treat in view of concerns about the efficacy and safety of interferon-based therapy. Nevertheless, antiviral therapy might have a substantial benefit in these patients as it potentially minimizes disease progression and prevents recurrence after liver transplantation. We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia. PATIENTS: Nine patients (M=8, age: 48.4 +/- 9.9, mean +/- SD) with HCV-related advanced liver disease and thrombocytopenia were prospectively investigated. The Child-Pugh stage was A in six patients and B in three, the MELD score was 11 [6-17] (median [range]). Four patients were interferon naive. HCV-genotype distribution was 1b (n=3), 3a (n=4) and 4 (n=2). The patients received 1-1.5 MU/d standard interferon-a2b with increasing dose regimen and weight-based ribavirin for 48 weeks (genotype 1), or 24 weeks (genotype 3), or until liver transplantation, respectively. RESULTS: The baseline platelet count was 64.3 +/- 8.7 (G/l, mean +/- SD) and remained remarkably stable during treatment (58.0 +/- 12.4 G/l at week 4, 51.7 +/- 20.5 G/l at week 8, P=0.1). All patients had adverse events such as weight loss, fever and anorexia. Hospitalization because of decompensation or infection was necessary in three patients. Three patients underwent liver transplantation. A virological response on treatment was achieved in eight patients and sustained in three (33.3%) patients. CONCLUSION: Treatment with standard interferon-alpha2b/ribavirin could be of benefit in patients with advanced liver cirrhosis and thrombocytopenia however, a vigilant monitoring of these high risk patients is mandatory.
BACKGROUND AND AIM: Patients with advanced liver disease due to thrombocytopenia and chronic infection with hepatitis C virus (HCV) are difficult to treat in view of concerns about the efficacy and safety of interferon-based therapy. Nevertheless, antiviral therapy might have a substantial benefit in these patients as it potentially minimizes disease progression and prevents recurrence after liver transplantation. We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia. PATIENTS: Nine patients (M=8, age: 48.4 +/- 9.9, mean +/- SD) with HCV-related advanced liver disease and thrombocytopenia were prospectively investigated. The Child-Pugh stage was A in six patients and B in three, the MELD score was 11 [6-17] (median [range]). Four patients were interferon naive. HCV-genotype distribution was 1b (n=3), 3a (n=4) and 4 (n=2). The patients received 1-1.5 MU/d standard interferon-a2b with increasing dose regimen and weight-based ribavirin for 48 weeks (genotype 1), or 24 weeks (genotype 3), or until liver transplantation, respectively. RESULTS: The baseline platelet count was 64.3 +/- 8.7 (G/l, mean +/- SD) and remained remarkably stable during treatment (58.0 +/- 12.4 G/l at week 4, 51.7 +/- 20.5 G/l at week 8, P=0.1). All patients had adverse events such as weight loss, fever and anorexia. Hospitalization because of decompensation or infection was necessary in three patients. Three patients underwent liver transplantation. A virological response on treatment was achieved in eight patients and sustained in three (33.3%) patients. CONCLUSION: Treatment with standard interferon-alpha2b/ribavirin could be of benefit in patients with advanced liver cirrhosis and thrombocytopenia however, a vigilant monitoring of these high risk patients is mandatory.
Authors: Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter Journal: Wien Klin Wochenschr Date: 2004-08-31 Impact factor: 1.704
Authors: J M Moreno Planas; E Rubio Gonzalez; E Boullosa Graña; A Garrido Botella; C Barrios Peinado; J L Lucena Poza; M Jiménez Garrido; V Sanchez Turrion; V Cuervas-Mons Martinez Journal: Transplant Proc Date: 2005-06 Impact factor: 1.066
Authors: Amandeep K Shergill; Mandana Khalili; Stephanie Straley; Kathy Bollinger; John P Roberts; Nancy A Ascher; Norah A Terrault Journal: Am J Transplant Date: 2005-01 Impact factor: 8.086
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Didier Samuel; Thierry Bizollon; Cyrille Feray; Bruno Roche; Si Nafa Si Ahmed; Catherine Lemonnier; Marielle Cohard; Michel Reynes; Michelle Chevallier; Christian Ducerf; Jacques Baulieux; Michael Geffner; Janice K Albrecht; Henri Bismuth; Christian Trepo Journal: Gastroenterology Date: 2003-03 Impact factor: 22.682
Authors: Ryan M Thomas; John J Brems; Grace Guzman-Hartman; Sherri Yong; Patricia Cavaliere; David H Van Thiel Journal: Liver Transpl Date: 2003-09 Impact factor: 5.799
Authors: Xavier Forns; Montserrat García-Retortillo; Trinidad Serrano; Anna Feliu; Francisco Suarez; Manuel de la Mata; Juan Carlos García-Valdecasas; Miquel Navasa; Antoni Rimola; Juan Rodés Journal: J Hepatol Date: 2003-09 Impact factor: 25.083
Authors: Kent W Kercher; Alfredo M Carbonell; B Todd Heniford; Brent D Matthews; Dawn M Cunningham; Robert W Reindollar Journal: J Gastrointest Surg Date: 2004-01 Impact factor: 3.452
Authors: Andreas Maieron; Sigrid Metz-Gercek; Franz Hackl; Alexander Ziachehabi; Harri Fuchsteiner; Christoph Luger; Helmut Mittermayer; Rainer Schöfl Journal: Wien Klin Wochenschr Date: 2010-04 Impact factor: 1.704